Resveratrol: A natural polyphenol with multiple chemopreventive properties (Review)

Current Drug Metabolism

Volumn 10, Issue 6, 2009, Pages 530-546

  Brisdelli, Fabrizia ^a   D'Andrea, Gabriele ^a   Bozzi, Argante ^a  

^a Consorzio INBB ^*

Author keywords

Anti cancer; Apoptosis; Cardioprotection; Chemoprevention; Neuroprotection; Polyphenols; Resveratrol

Indexed keywords

AMYLOID BETA PROTEIN; CD147 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PACLITAXEL; PEROXYNITRITE; PROTEIN BCL 2; PROTEIN BCL XL; RESVERATROL;

ALZHEIMER DISEASE; ANTIARRHYTHMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; BRAIN PROTECTION; BREAST CANCER; CANCER CELL; CANCER PREVENTION; CANCER RESISTANCE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; CELL PROTECTION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHEMOSENSITIZATION; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; GENOTOXICITY; HEART ARRHYTHMIA; HEART PROTECTION; HORMONE ACTION; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN CARCINOGENESIS;

ANTIOXIDANTS; MOLECULAR STRUCTURE; STILBENES;

EID: 70450123699     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789375423     Document Type: Review

References (233)

1. Dercks, W.; Creasy, L.L. The significance of stilbene phytoalexins in the Plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Pathol., 1989, 34(3), 189-202.
2. Dercks, W.; Creasy, L.L. Influence of fosetyl-Al on phytoalexin accumulation in the Plasmopara viticola - grapevine interaction. Physiol. Mol. Plant Pathol., 1989, 34(3), 203-213.
3. Jeandet, P.; Bessis, R.; Gautheron, B. The production of resveratrol (3,5,4′-trihydroxystilbene) by grape berries in different developmental stages. Am. J. Enol. Viti., 1991, 42(1), 41-46.
4. Goldberg, D.M.; Yan, J.; Ng, E.; Diamandis, E.P.; Karumanchiri, A.; Soleas, G.; Waterhouse, A.L. A Global survey of trans-resveratrol concentrations in commercial wines. Am. J. Enol. Viti., 1995, 46(2), 159-165.
5. Romero-Perez, A.I.; Lamuela-Raventos, R.M.; Waterhouse, A.L.; de la Torre-Boronat, M.C. Levels of cis- and trans-resveratrol and their glucosides in white and rosé Vitis vinifera wines from Spain. J. Agric. Food Chem., 1996, 44(8), 2124-2128.
6. Langcake, P.; Pryce, R.J. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol. Plant Pathol., 1976, 9(1), 77-86.
7. Siemann, E.H.; Creasy, L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic., 1992, 43(1), 49-52.
8. Moreno-Labanda, J.F.; Mallavia, R.; Perez-Fons L.; Lizama, V.; Saura, D.; Micol, V. Determination of Piceid and Resveratrol in Spanish Wines Deriving from Monastrell (Vitis vinifera L.) Grape Variety. J. Agric. Food Chem., 2004, 52 (17), 5396-5403.
9. Burns, J.; Yokota, T.; Ashihara, H.; Lean, M.E.; Crozier, A. Plant Foods and Herbal Sources of Resveratrol. J. Agric. Food Chem., 2002, 50(11), 3337-3340.
10. Regev-Shoshani, G.; Shoseyov, O.; Bilkis, I.; Kerem, Z. Glycosylation of resveratrol protects it from enzymic oxidation. Biochem. J., 2003, 374(Pt 1), 157-163. (Pubitemid 37046939)
11. Krasnow, M.N.; Murphy, T.M. Polyphenol glucosylating activity in cell suspensions of grape (Vitis vinifera). J. Agric. Food Chem., 2004, 52(11), 3467-3472.
12. Signorelli, P.; Ghidoni, R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem., 2005, 16(8), 449-466. (Pubitemid 41039220)
13. Goldberg, D.M.; Hahn, S.E.; Parkes, J.G. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin. Chim. Acta, 1995, 237(1-2), 155-187.
14. Jang, M.; Cai, L; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Metha, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275(5297), 218-220. (Pubitemid 127696281)
15. Clement, M.V.; Hirpara, J.L.; Chawdhury, S.H.; Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 1998, 92(3), 996-1002. (Pubitemid 28355484)
16. Carbo, N.; Costelli, P.; Baccino, F.M.; Lopez-Soriano, F.J.; Argiles, J.M. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun., 1999, 254(3), 739-743.
17. Wadsworth, T.L.; Koop, D.R. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol., 1999, 57(8), 941-949.
18. Park, J.W.; Choi, Y.J.; Jang, M.A.; Lee, Y.S.; Jun, D.Y.; Suh, S.I.; Baek, W.K.; Suh, M.H.; Jin, I.N.; Kwon, T.K. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett., 2001, 163(1), 43-49.
19. Bowers, J.L.; Tyulmenkov, V.V.; Jernigan, S.C.; Klinge, C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology, 2000, 141(10), 3657-3667.
20. Ray, P.S.; Maulik, G.; Cordis, G.A.; Bertelli, A.A.; Bertelli, A.; Das, D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med., 1999, 27(1-2), 160-169.
21. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, M.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24(5A), 2783-2840. (Pubitemid 39409568)
22. Fremont L. Biological effects of resveratrol. Life Sci., 2000, 66(8), 663-673.
23. Fitzpatrick, D.F.; Hirschfield, S.L.; Coffey, R.G. Endotheliumdependent vasorelaxing activity of wine and other grape products. Am. J. Physiol., 1993, 265(2 Pt 2), H774-H778.
24. Frankel, E.N.; Kanner, J.; German, J.B.; Parks, E.; Kinsella, J.E. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet, 1993 341(8843), 454-457. (Pubitemid 23054518)
25. Kondo, K.; Matsumoto, A.; Kurata, H.; Tanahashi, H.; Koda, H.; Amachi, T.; Itakura, H. Inhibition of oxidation of low-density lipoprotein with red wine. Lancet, 1994, 344(8930), 1152. (Pubitemid 24317640)
26. Orallo, F.; Alvarez, E.; Camina, M.; Leiro, J.M.; Gomez, E.; Fernandez, P. The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol., 2002, 61(2), 294-302. (Pubitemid 34112803)
27. Pace-Asciak, C.R.; Hahn, S.E.; Diamandis, E.P.; Soleas, G.; Goldberg, D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta, 1995, 235(2), 207-219.
28. Wang, Z.; Zou, J.; Huang, Y.; Cao, K.; Xu, Y.; Wu, J.M. Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin. Med. J. (Engl.), 2002, 115(3), 378-380. (Pubitemid 34272437)
29. Steinberg, D.; Parthasarathy, S.; Carew, T.E.; Khoo, J.C.; Witztum, J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med., 1989, 320(14), 915-924.
30. Ferrero, M.E.; Bertelli, A.E.; Fulgenti, A.; Pellegatta, F.; Corsi, M.M.; Bonfrate, M.; Ferrara, F.; De Caterina, R.; Giovannini, L.; Bertelli, A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr., 1998, 68(6), 1208-1214. (Pubitemid 28550950)
31. Jang, D.S.; Kang, B.S.; Ryu, S.Y.; Chang, I.M.; Min, K.R.; Kim, Y. Inhibitory effects of resveratrol analogs on unopsonized zymosan- induced oxygen radical production. Biochem. Pharmacol., 1999, 57(6), 705-712. (Pubitemid 29080762)
32. Belguendouz, L.; Fremont, L.; Linard, A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol., 1997, 53(9), 1347-1355. (Pubitemid 27305634)
33. Chanvitayapongs, S.; Sun, A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. NeuroReport, 1997, 8(6), 1499-1502. (Pubitemid 27242563)
34. Jang, M.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res., 1999, 25(2-3), 65-77.
35. Zhong, M.; Cheng, G.F.; Wang, W.J.; Guo, Y.; Zhu, X.Y.; Zhang, J.T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine, 1999, 6(2), 79-84.
36. Tsai, S.H.; Lin-Shiau, S.Y.; Lin, J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol., 1999, 126(3), 673-680. (Pubitemid 29087846)
37. Hsieh, T.C.; Juan, G.; Darzynkievicz, Z.; Wu, J.M. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res., 1999, 59(11), 2596-2601.
38. Mitchell, S.H.; Zhu, W.; Young, C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res., 1999, 59(23), 5892-5895. (Pubitemid 30004946)
39. Kaga, S.; Zhan, L.; Matsumoto, M.; Maulik, N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol., 2005, 39(5), 813-822. (Pubitemid 41464418)
40. Li, H.; Forstermann, U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol., 2000, 190(3), 244-254. (Pubitemid 30141371)
41. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation, 2002, 106(13), 1652-1658.
42. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420(6917), 868-874.
43. Wung, B.S.; Hsu, M.C.; Wu, C.C.; Hsieh, C.W. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci., 2005, 78(4), 389-397.
44. Cooke, J.P. Flow, NO, and atherogenesis. Proc. Natl. Acad. Sci. USA, 2003, 100(3), 768-770.
45. Cai, H.; Harrison, D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87(10), 840-844.
46. Ischiropoulos, H.; al-Mehdi, A.B. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett., 1995, 364(3), 279-282.
47. Ischiropoulos, H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem. Biophys. Res. Commun., 2003, 305(3), 776-783. (Pubitemid 36581936)
48. Ducrocq, C.; Blanchard, B.; Pignatelli, B.; Oshima, H. Peroxynitrite: an endogenous oxidizing and nitrating agent. Cell. Mol. Life Sci., 1999, 55(8-9), 1068-1077.
49. Reiter, C.D.; Teng, R.J.; Beckman, J.S. Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem., 2000, 275(42), 32460-32466.
50. Olas, B.; Nowak, P.; Wachowicz, B. Resveratrol protects against peroxynitrite-induced thiol oxidation in blood platelets. Cell. Mol. Biol. Lett., 2004, 9(4A), 577-587. (Pubitemid 40065185)
51. Olas, B; Nowak, P.; Kolodziejkzyk, J.; Ponczek, M.; Wachowicz, B. Protective effects of resveratrol against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite. J. Nutr. Biochem., 2006, 17(2), 96-102. (Pubitemid 43082143)
52. Virag, L.; Szabo, E.; Gergely, P.; Szabo, C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol. Lett., 2003, 140-141, 113-124. (Pubitemid 36378929)
53. Brito, P.M.; Mariano, A.; Almeida, L.M.; Dinis, T.C. Resveratrol affords protection against peroxynitrite-mediated endothelial cell death: A role for intracellular glutathione. Chem. Biol. Interact., 2006, 164(3), 157-166.
54. Brito, P.M.; Simoes, N.F.; Almeida, L.M.; Dinis, T.C. Resveratrol disrupts peroxynitrite-triggered mitochondrial apoptotic pathway: a role for Bcl-2. Apoptosis, 2008, 13(8), 1043-1053.
55. Huang, Z.; Wang, C.; Wei, L.; Wang, J.; Fan, Y.; Wang, L.; Wang, Y.; Chen, T. Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem. Biophys. Res. Commun., 2008, 374(3), 517-521.
56. Schmidt, R.; Bultmann, A.; Ungerer, M.; Joghetaei, N.; Bulbul O.; Thieme, S.; Chavakis, T.; Toole B.P.; Gawaz M.; Schomig A.; May A.E. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation, 2006, 113(6), 834-841.
57. Major, T.C.; Liang, L.; Lu, X.; Rosebury ,W.; Bocan, T.M. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler. Thromb. Vasc. Biol., 2002, 22(7), 1200-1207.
58. Haug, C.; Lenz, C.; Diaz, F.; Bachem M.G. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase Inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24(10), 1823-1829.
59. Ge, H.; Zhang, J.F.; Guo, B.S.; He, Q.; Wang, B.Y.; He, B.; Wang, C.Q. Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma. Vascul. Pharmacol., 2007, 46(2), 114-141.
60. Hu, E.; Kim, J.B.; Sarraf, P.; Spiegelman, B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science, 1996, 274(5295), 2100-2103.
61. Camp, H.S.; Tafuri, S.R. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J. Biol. Chem., 1997, 272(16), 10811-10816.
62. Adams, M.; Reginato, M.J.; Shao, D.; Lazar, M.A.; Chatterjee, V.K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem., 1997, 272(8), 5128-5132.
63. Zhang, Y.; Liu, Y.; Wang, T.; Li, B.; Li, H.; Wang, Z.; Yang, B. Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. Biochem. Biophys. Res. Commun., 2006, 340(4), 1192-1199.
64. Yang, B.F.; Lin, H.X.; Xu, C.Q.; Liu, X.; Wang, H.Z.; Han, H.; Wang, Z.G. Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac m3 subtype muscarinic acetylcholine receptors. Cell. Physiol. Biochem., 2005, 16(4-6), 163-174.
65. Shan, H.L.; Yang, B.F.; Zhou, Y.H.; Wang, H.; Li, B.X. Effects of matrine on aconitine-induced electrophysiological changes in rat ventricular myocytes. J. Chinese Pharm. Sci., 2004, 13(3), 193-198.
66. Pousti, A.; Deemyad, T.; Brumand, K.; Bakhtiarian, A. The effect of fluvoxamine on ouabain-induced arrhythmia in isolated guinea-pig atria. Pharmacol. Res., 2005, 52(2), 151-153. (Pubitemid 40828365)
67. Ono, M.; Nakamura, N.; Koga, Y. KB-R9032, newly developed Na+/H+ exchange inhibitor, attenuates reperfusion-induced arrhythmias in isolated perfused rat heart. J. Anesth., 2004, 18(3), 196-202. (Pubitemid 39264212)
68. Valtchanova-Matchouganska, A.; Missankov, A.; Ojewole, J.A. Evaluation of the antidysrhythmic effects of delta- and kappaopioid receptor agonists and antagonists on calcium chloride-, adrenaline- and ischemia/reperfusion-induced arrhythmias in rats. Methods Find. Exp. Clin. Pharmacol., 2004, 26(1), 31-38.
69. Hanna, J.; Chahine, R.; Aftimos, G.; Nader, M; Mounayar, A.; Esseily, F.; Chamat, S. Protective effect of taurine against free radicals damage in the rat myocardium. Exp. Toxicol. Pathol., 2004, 56(3), 189-194. (Pubitemid 39627969)
70. Tatlidede, E.; Sehirli, O.; Velioǧlu-Oǧunc, A.; Cetinel, S.; Yeǧen, B.C.; Yarat, A.; Suleymanoǧlu, S.; Sener, G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic. Res., 2009, 43(3), 195-205.
71. Zha, X.-Y.; Li, G.-Y.; Liu, Y.; Chai, L.-M.; Chen, J.-X.; Zhang, Y. ; Du, Z.-M.; Lu, Y.-J. ; Yang, B.-F. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br. J. Pharmacol., 2008, 154(1), 105-113.
72. Ramassamy, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol., 2006, 545(1), 51-64. (Pubitemid 44236172)
73. Youdim, K.A.; Joseph, J.A. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radic. Biol. Med., 2001, 30(6), 583-594.
74. Abd El Moshen, M.M.; Kuhnle, G.; Rechner, A.R.; Schroeter, H.; Rose, S.; Jenner, P.; Rice-Evans, C.A. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic. Biol. Med., 2002, 33(12), 1693-1702.
75. Orgogozo, J.M.; Dartigues, J.F.; Lafont, S.; Letenneur, L.; Commenges, D.; Salamon, R.; Renaud, S.; Bretler, M.B. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev. Neurol. (Paris), 1997, 153(3), 185-192.
76. Truelsen, T.; Thudium, D.; Gronbaek, M. Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology, 2002, 59(9), 1313-1319. (Pubitemid 35285979)
77. Lindsay, J.; Laurin, D.; Verreault, R.; Hebert, R.; Helliwell, B.; Hill, G.B.; McDowell, I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol., 2002, 156(5), 445-453. (Pubitemid 34976983)
78. Luchsinger, J.A.; Tang, M.X.; Siddiqui, M.; Shea, S.; Mayeux, R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc., 2004, 52(4), 540-546.
79. Savaskan, E.; Olivieri, G.; Meier, F.; Seifritz, E.; Wirz-Justice, A.; Muller-Spahn, F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology, 2003, 49(6), 380-383. (Pubitemid 37465118)
80. Jang, J.H.; Surh, Y.J. Protective effect of resveratrol on betaamyloid- induced oxidative PC12 cell death. Free Radic. Biol. Med., 2003, 34(8), 1100-1110.
81. Han, Y.S.; Zheng, W.H.; Bastianetto, S.; Chabot, J.G.; Quirion, R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol., 2004, 141(6), 997-1005. (Pubitemid 38510083)
82. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185.
83. Behl, C.; Davis, J.; Cole, G.M.; Schubert, D. Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun., 1992, 186(2), 944-950.
84. Kaltschmidt, B.; Uherek, M.; Volk, B.; Baeurle, P.A.; Kaltschmidt, C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1997, 92(6), 2642-2647. (Pubitemid 27136929)
85. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem., 2005, 280(45), 37377-37382. (Pubitemid 41642343)
86. Keller, J.N.; Hanni, K.B.; Markesbery, W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem., 2000, 75(1), 436-439. (Pubitemid 30418211)
87. Lopez Salon, M.; Morelli, R.; Castano, E.M.; Soto, E.F.; Pasquini, J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosi. Res., 2000, 62(2), 302-310.
88. Gregori, L.; Fuchs, C.; Figueiredo-Pereira, M.E.; Van Nostrand, W.E.; Goldgaber, D. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem., 1995, 270(34), 19702-19708.
89. Guarente, L. SIR2 and aging - the exception that proves the rule. Trends Genet., 2001, 17(7), 391-392. (Pubitemid 32545384)
90. Anekonda, T.S.; Reddy, P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem., 2006, 96(2), 305-313.
91. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280(48), 40364-40374. (Pubitemid 41779174)
92. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J., 2003, 17(14), 1975-1985.
93. Parker, J.A.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 2005, 37(4), 349-350. (Pubitemid 40490482)
94. Borrell-Pages, M.; Zala, D.; Humbert, S.; Saudou, F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci., 2006, 63(22), 2642-2660. (Pubitemid 44800717)
95. Conte, A.; Pellegrini, S.; Tagliazucchi, D. Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin. Brain Res. Bull., 2003, 62(1), 29-38. (Pubitemid 37330112)
96. Aquilano, K.; Baldelli, S.; Rotilio, G.; Ciriolo, M.R. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res., 2008, 33(12), 2416-2426.
97. Lu, K.T.; Ko, M.C.; Chen, B.Y.; Huang, J.C.; Hsieh, C.W.; Lee, M.C.; Chiou, R.Y.; Wung, B.S.; Peng, C.H.; Yang Y.L. Neuroprotective effects of resveratrol on mptp-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem., 2008, 56(16), 6910-6913.
98. Kundu, J.K.; Surh, Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett., 2008, 269(2), 243-261.
99. Bhat, K.P.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol. Ann. N.Y. Acad. Sci., 2002, 957, 210-229.
100. Tessitore, L.; Davit, A.; Sarotto, I.; Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis, 2000, 21(8), 1619-1622. (Pubitemid 30608219)
101. Mgbonyebi, O.P.; Russo, J.; Russo, I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol., 1998, 12(4), 865-869.
102. Della Ragione, F.D.; Cucciolla, V.; Borriello, A.; Pietra, V.D.; Racioppi, L.; Soldati, G.; Manna, C.; Galletti, P.; Zappia, V. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun., 1998, 250(1), 53-58.
103. Hsieh, T.C.; Burfeind, P.; Laud, K.; Backer, J.M.; Traganos, F.; Darzynkiewicz, Z.; Wu, J.M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol., 1999, 15(2), 245-252.
104. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62(17), 4945-4954.
105. Bhat, K.P.; Lantvit, D.; Christov, K.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 2001, 61(20), 7456-7463.
106. Bhat, K.P.; Pezzuto, J.M. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res., 2001, 61(16), 6137-6144.
107. Bhat, K.P.; Kosmeder, J.W.; Pezzuto, J.M. Biological effects of resveratrol. Antioxid. Redox Signal., 2001, 3(6), 1041-1064.
108. Joe, A.K.; Liu, H.; Suzui, M.; Vural, M.; Xiao, D.; Weinstein, I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res., 2002, 8(3), 893-903.
109. Sgambato, A.; Ardito, R.; Faraglia, B.; Boninsegna, A.; Wolf, F.I.; Cittadini, A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat. Res., 2001, 496(1-2), 171-180.
110. Larrosa, M.; Tomas-Barberan, F.A.; Espin, J.C. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J. Agric. Food Chem., 2003, 51(16), 4576-4584.
111. Ahmad, N.; Adhami, V.M.; Afaq, F.; Feyes, D.K.; Mukhtar, H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res., 2001, 7(5), 1466-1473. (Pubitemid 32708704)
112. Liang, Y.C.; Tsai, S.H.; Chen, L.; Lin-Shiau, S.Y.; Lin, J.K. Resveratrol- induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol., 2003, 65(7), 1053-1060.
113. Jazirehi, A.R.; Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther., 2004, 3(1), 71-84. (Pubitemid 39193680)
114. Fulda, S.; Debatin, K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 2004, 23(40), 6702-6711
115. Gautam, S.C.; Xu, Y.X.; Dumaguin, M.; Janakiraman, N.; Chapman, R.A. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Traspl., 2000, 25(6), 639-645.
116. Gusman, J.; Malonne, H.; Atassi, G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 2001, 22(8), 1111-1117. (Pubitemid 32737324)
117. Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett., 1998, 421(3), 277-279.
118. Collins, I.; Garrett, M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol., 2005, 5(4), 366-373.
119. Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr., 2001, 131(8), 2197-2203. (Pubitemid 32720652)
120. Reagan-Shaw, S.; Afaq, F.; Aziz, M.H.; Ahmad, N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene, 2004, 23(30), 5151-5160. (Pubitemid 38980348)
121. Kim, Y.A.; Rhee, S.H.; Park, K.Y.; Choi, Y..H. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food., 2003, 6(4), 273-280. (Pubitemid 38114319)
122. Kim, Y.A.; Choi, B.T.; Lee, Y.T.; Park, D.I.; Rhee, S.H.; Park, K.Y.; Choi, Y.H. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol. Rep., 2004, 11(2), 441-446.
123. Kim, Y.A.; Lee, W.H.; Choi, T.H.; Rhee, S.H.; Park, K.Y.; Choi, Y.H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int. J. Oncol., 2003, 23(4), 1143-1149.
124. Adhami, V.M.; Afaq, F.; Ahmad, N. Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem. Biophys. Res. Commun., 2001, 288(3), 579-585. (Pubitemid 33030069)
125. Stewart, J.R.; Ward, N.E.; Ioannides, C.G.; O'Brian, C.A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry, 1999, 38(40), 13244-13251. (Pubitemid 129515647)
126. Kalra, N.; Roy, P.; Prasad, S,; Shukla, Y. Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci., 2008, 82(7-8), 348-358.
127. Garvin, S.; Ollinger, K.; Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett., 2006, 231(1), 113-122. (Pubitemid 41779459)
128. Cal, C.; Garban, H.; Jazirehi, A.; Yeh, C.; Mizutani, Y.; Bonavida, B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr. Med. Chem. Anticancer Agents, 2003, 3(2), 77-93.
129. Zheng, J.; Ramirez, V.D. Inhibition of mitochondrial proton F0F1- ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol., 2000, 130(5), 1115-1123.
130. Murphy, E.; Imahashi, K.; Steenbergen, C. Bcl-2 regulation of mitochondrial energetics. Trends Cardiovasc. Med., 2005, 15(8), 283-290.
131. Oltvai, Z.N.; Milliman, C.L.; Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 1993, 74(4), 609-1519
132. Korsmeyer, S.J. Regulators of cell death. Trends Genet., 1995, 11(3), 101-105.
133. Levine, B.; Goldman, J.E.; Jiang, H.H.; Griffin, D.E.; Hardwick, J.M. Bcl-2 protects mice against fatal alphavirus encephalitis. Proc. Natl. Acad. Sci. USA, 1996, 93(10), 4810-4815.
134. Haldar, S.; Basu, A.; Croce, C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res., 1997, 57(2), 229-233.
135. Srivastava, R.K.; Sasaki, C.Y.; Hardwick, J.M.; Longo, D.L. Bcl-2- mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J. Exp. Med., 1999, 190(2), 253-265.
136. Srivastava, R.K.; Sollott, S.J.; Khan, L.; Hansford, R.; Lakatta, E.G.; Longo, D.L. Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Mol. Cell. Biol., 1999, 19(8), 5659-5674.
137. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2002, 2(4), 301-310.
138. Lilienbaum, A.; Israel, A. From calcium to NF-kappa B signaling pathways in neurons. Mol. Cell Biol., 2003, 23(8), 2680-2698. (Pubitemid 36403070)
139. Yamamoto, Y.; Gaynor, R.B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci., 2004, 29(2), 72-79.
140. Moon, S.K.; Kim, H.M.; Kim, C.H. PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NFkappaB and AP-1 in vascular smooth muscle cells. Arch. Biochem. Biophys., 2004, 421(2), 267-276.
141. Yang, J.Q.; Zhao, W.; Duan, H.; Robbins, M.E.; Buettner, G.R.; Oberley, L.W.; Domann, F.E. v-Ha-RaS oncogene upregulates the 92-kDa type IV collagenase (MMP-9) gene by increasing cellular superoxide production and activating NF-kappaB. Free Radic. Biol. Med., 2001, 31(4), 520-529.
142. Van der Heiden, M.G.; Thompson, C.B. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat. Cell Biol., 1999, 1(8), 209-216.
143. Kroemer, G.; Reed, J.C. Mitochondrial control of cell death. Nat. Med., 2000, 6(5), 513-519. (Pubitemid 30305900)
144. Desagher, S.; Martinou, J.C. Mitochondria as the central control point of apoptosis. Trends Cell Biol., 2000, 10(9), 369-377.
145. Marzo, I.; Brenner, C.; Zamzami, N.; Jurgensmeier, J.M.; Susin, S.A.; Vieira, H.L.; Prevost, M.C.; Xie, Z.; Matsuyama, S.; Reed, J.C.; Kroemer, G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science, 1998, 281(5385), 2027-2031.
146. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J., 1999, 341(Pt 2), 233-249. (Pubitemid 29373645)
147. Brenner, C.; Cadiou, H.; Vieira, H.L.; Zamzami, N.; Marzo, I.; Xie, Z.; Leber, B.; Andrews, D.; Duclohier, H.; Reed, J.C.; Kroemer, G. Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator.Oncogene, 2000, 19(3), 329-336.
148. Zunino, S.J.; Storms, D.H. Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett., 2006, 240(1), 123-134.
149. Mahyar-Roemer, M.; Katsen, A.; Mestres, P.; Roemer, K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer, 2001, 94(5), 615-622. (Pubitemid 33035679)
150. Mahyar-Roemer, M.; Kohler, H.; Roemer, K. Role of Bax in resveratrol- induced apoptosis of colorectal carcinoma cells. BMC Cancer, 2002, 2, 27-35.
151. Makin, G.W.; Corfe, B.M.; Griffiths, G.J.; Thistlethwaite, A.; Hickman, J.A.; Dive, C. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/ complexes occur regardless of cell fate. EMBO J., 2001, 20(22), 6306-6315. (Pubitemid 33078704)
152. Riles, W.L.; Erickson, J.; Nayyar, S.; Atten, M.J.; Attar, B.M.; Holian, O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J. Gastroenterol., 2006, 12(35), 5628-5634. (Pubitemid 44594036)
153. Luzi, C.; Brisdelli, F.; Cinque, B.; Cifone, G.; Bozzi, A. Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells. Biochem. Pharmacol., 2004, 68(10), 2019-2030. (Pubitemid 39346192)
154. Opipari, A.W.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A.; Liu, J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res., 2004, 64(2), 696-703. (Pubitemid 38120912)
155. Surh, Y.J.; Hurh, Y.J.; Kang, J.Y.; Lee, E.; Kong, G.; Lee, S.J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett., 1999, 140(1-2), 1-10. (Pubitemid 29251307)
156. Mouria, M.; Gukovskaya, A.S.; Jung, Y.; Buechler, P.; Hines, O.J.; Reber, H.A.; Pandol, S.J. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int. J. Cancer, 2002, 98(5), 761-769.
157. Dorrie, J.; Gerauer, H.; Wachter, Y.; Zunino, S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res., 2001, 61(12), 4731-4739.
158. Bratton, S.B.; Walker, G.; Srinivasula, S.M.; Sun, X.M.; Butterworth, M.; Alnemri, E.S.; Cohen, G.M. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J., 2001, 20(5), 998-1009.
159. Zou, H.; Henzel, W.J.; Liu, X.; Lutschg, A.; Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 1997, 90(3), 405-413.
160. Janicke, R.U.; Sprengart, M.L.; Wati, M.R.; Porter, A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 1998, 273(16), 9357-9360.
161. Delmas, D.; Rebe, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkauoi-Malki, M.; Jannin, B. ; Dubrez-Daloz, L.; Latruffe, N.; Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem., 2003, 278(42), 41482-41490.
162. Fulda, S.; Debatin, K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64(1), 337-346. (Pubitemid 38114116)
163. Fehsel, K.; Kroncke, K.D.; Meyer, K.L.; Huber, H.; Wahn, V.; Kolb-Bachofen, V. Nitric oxide induces apoptosis in mouse thymocytes. J. Immunol., 1995, 155(6), 2858-2865.
164. Brune, B.; von Knethen, A.; Sandau, K.B. Nitric oxide (NO): an effector of apoptosis. Cell Death Differ., 1999, 6(10), 969-975.
165. Nicotera, P.; Melino, G. Regulation of the apoptosis-necrosis switch. Oncogene, 2004, 23(16), 2757-2765.
166. Kampa, M.; Hatzoglou, A.; Notas, G.; Damianaki, A.; Bakogeorgou, E.; Gemetzi, C.; Kouroumalis, E.; Martin, P.M.; Castanas, E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr. Cancer, 2000, 37(2), 223-233.
167. Agarwal, R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol., 2000, 60(8), 1051-1059.
168. Shankar, S.; Siddiqui, I.; Srivastava, R.K. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol. Cell. Biochem., 2007, 304(1- 2), 273-285.
169. Narayanan, B.A.; Narayanan, N.K.; Re, G.G.; Nixon, D.W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer, 2003, 104(2), 204-212.
170. Scarlatti, F.; Sala, G.; Somenzi, G.; Signorelli, P.; Sacchi, N.; Ghidoni, R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J., 2003, 17(15), 2339-2341. (Pubitemid 39561486)
171. Sala, G.; Minatolo, F.; Macchia, M.; Sacchi, N.; Guidoni, R. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drug. Exp. Clin. Res., 2003, 29(5-6), 263-2699.
172. Hannun, Y.A.; Luberto, C.; Argraves, K.M. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry, 2001, 40(16), 4893-4903.
173. Michels, G.; Watjen, W.; Weber, N.; Niering, P.; Chovolou, Y.; Kampkotter, A.; Proksch, P.; Kahl, R. Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Toxicology, 2006, 225(2-3), 173-182. (Pubitemid 44108376)
174. Garg, A.K. ; Buchholz, T.A.; Aggarwal, B.B. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid. Redox Signal., 2005, 7(11-12), 1630-1647.
175. Bebawy, M.; Morris, M.B.; Roufogalis, B.D. Selective modulation of P-glycoprotein-mediated drug resistance. Br. J. Cancer, 2001, 85(12), 1998-2003.
176. Nooter, K.; Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract., 1996, 192(7), 768-780. (Pubitemid 26302251)
177. Sandor, V.; Wilson, W.; Fojo, T.; Bates, S.E. The role of MDR-1 in refractory lymphoma. Leuk. Lymphoma, 1997, 28(1-2), 23-31.
178. Emmanouilides, C.; Jazirehi, A.; Bonavida, B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother. Radiopharm., 2002, 17(6), 621-630. (Pubitemid 36025943)
179. Goss, P.; Stewart, A.K.; Couture, F.; Klasa, R.; Gluck, S.; Kaizer, L.; Burkers, R.; Charpentier, D.; Palmer, M.; Tye, L.; Dulude, H. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk. Lymphoma, 1999, 34(3-4), 295-304. (Pubitemid 29385172)
180. Miller, H.J.; Leong, T.; Khandekar, J.D.; Greipp, P.R.; Gertz, M.A.; Kyle, R.A. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study (E1A93). Am. J. Clin. Oncol., 1998, 21(6), 553-556.
181. Jazirehi, A.R.; Ng, C.P.; Gan, X.H.; Schiller, G.; Bonavida, B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin. Cancer Res., 2001, 7(12), 3874-3883. (Pubitemid 34044604)
182. Ng, C.P.; Bonavida, B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv. Cancer Res., 2002, 85, 145-174.
183. Kudla, G.; Montessuit, S.; Eskes, R.; Berrier, C.; Martinou, J.C.; Ghazi, A.and Antonsson, B. The destabilization of lipid membranes induced by the C-terminal fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment. J. Biol. Chem., 2000, 275(30), 22713-22718.
184. Korsmeyer, S.J.; Wei, M.C.; Saito, M.; Weiler, S.; Oh, K.J.; Schlesinger, P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ., 2000, 7(12), 1166-1173.
185. De Feudis, P.; Vignati, S.; Rossi, C.; Mincioni, T.; Gavazzi, R.; D'Incalci, M.; Broggini, M. Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. Neoplasia, 2000, 2(3), 202-207. (Pubitemid 30346076)
186. Tsuruta, Y.; Mandai, M.; Konishi, I.; Kuroda, H.; Kusakari, T.; Yura, Y.; Hamid, A.A.; Tamura, I.; Kariya, M.; Fujii, S. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur. J. Cancer, 2001, 37(4), 531-541. (Pubitemid 32232119)
187. Szocinski, J.L.; Khaled, A.R.; Hixon, J.; Halverson, D.; Funakoshi, S.; Fanslow, W.C.; Boyd, A.; Taub, D.D.; Durum, S.K.; Siegall, C.B.; Longo, D.L.; Murphy, W.J. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood, 2002, 100(1), 217-223.
188. Strobel, T.; Swanson, L.; Korsmeyer, S.; Cannistra, S.A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA, 1996, 93(24), 14094-14099.
189. Strobel, T.; Kraeft, S.K.; Chen, L.B.; Cannistra, S.A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res., 1998, 58(21), 4776-4781.
190. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun., 2005, 327(3), 866-870. (Pubitemid 40092828)
191. Schmitt, E.; Lehmann, L.; Metzler, M.; Stopper, H. Hormonal and genotoxic activity of resveratrol. Toxicol. Lett., 2002, 136(2), 133-142.
192. Matsuoka, A.; Furuta, A.; Ozaki, M.; Fukuhara, K.; Miyata, N. Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung (CHL) cell line. Mutat. Res., 2001, 494(1-2), 107-113.
193. Matsuoka, A.; Takeshita, K.; Furuta, A.; Ozaki, M.; Fukuhara, K.; Miyata, N. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat. Res., 2002, 521(1-2), 29-35. (Pubitemid 35346341)
194. Cadenas, S.; Barja, G. Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Radic. Biol. Med., 1999, 26(11-12), 1531-1537.
195. Williams, L.D.; Burdock, G.A.; Edwards, J.A.; Beck, M.; Bausch, J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem. Toxicol., 2009, 47(9), 2170-2182.
196. Bertelli, A.; Giovannini, L.; Stradi, R.; Tillement, J.P. Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4′,5- trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React., 1996, 18(2-3), 67-71. (Pubitemid 27121767)
197. Bertelli, A.A.; Giovannini, L.; Stradi, R.; Tillement, J.P.; Bertelli, A. Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin. Pharmacol. Res., 1996, 16(4-5), 77-81. (Pubitemid 27217776)
198. Fukuhara, K.; Miyata, N. Resveratrol as a new type of DNA-cleaving agent. Bioorg. Med. Chem. Lett., 1998, 8(22), 3187-3193.
199. Seike, K.; Murata, M.; Oikawa, S.; Hiraku, Y.; Hirakawa, K.; Kawanishi, S. Oxidative DNA damage induced by benz[a]anthracene metabolites via redox cycles of quinone and unique non-quinone. Chem. Res. Toxicol., 2003, 16(11), 1470-1476. (Pubitemid 37464469)
200. Wang, M.; Jin, Y.; Ho, C.T. Evaluation of resveratrol derivatives as potential antioxidants and identification of a reaction product of resveratrol and 2, 2-diphenyl-1-picryhydrazyl radical. J. Agric. Food Chem., 1999, 47(10), 3974-3977.
201. Azmi, A.S.; Bhat, S.H.; Hadi, S.M. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett., 2005, 579(14), 3131-3135.
202. Fukuhara, K.; Nagakawa, M.; Nakanishi, I.; Ohkubo, K.; Imai, K.; Urano, S.; Fukuzumi, S.; Ozawa, T.; Ikota, N.; Mochizuki, M.; Miyata, N.; Okuda, H. Structural basis for DNA-cleaving activity of resveratrol in the presence of Cu(II). Bioorg. Med. Chem., 2006, 14(5), 1437-1443. (Pubitemid 43120280)
203. Knight, D.C.; Eden, J.A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol., 1996, 87(5 Pt2), 897-904.
204. Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, Y.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA, 1997, 94(25), 14138-14143.
205. Ashby, J.; Tinwell, H.; Pennie, W.; Brooks, A.N.; Lefevre, P.A.; Beresford, N.; Sumpter, J.P. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J. Appl. Toxicol., 1999, 19(1), 39-45.
206. Lu, R.; Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol., 1999, 179(3), 297-304. (Pubitemid 29203154)
207. Su, J.L.; Yang, C.Y.; Zhao, M.; Kuo, M.L.; Yen, M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J. Biol. Chem., 2007, 282(27), 19385-19398.
208. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Karla, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puiqserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444 (7117), 337-342.
209. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127(6), 1109-1122. (Pubitemid 44894520)
210. Su, H.C.; Hung, L.M.; Chen, J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab., 2006, 290 (6), E1339-1346.
211. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell. Metab., 2007, 6(4), 307-319. (Pubitemid 47468091)
212. Park, C.E.; Kim, M.J.; Lee, J.H.; Min, B.I.; Bae, H.; Choe, W.; Kim, S.S.; Ha, J. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med., 2007, 39(2), 222-229. (Pubitemid 46683408)
213. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5(6), 493-506.
214. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450(7170), 712-716.
215. Zhang, J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem., 2007, 282(47), 34356-34364. (Pubitemid 350159485)
216. Breen, D.M.; Sanli, T.; Giacca, A.; Tsiani, E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun., 2008, 374 (1), 117-122.
217. Zahid, M.; Gaikwad, N.W.; Ali, M.F.; Lu, F.; Saeed, M.; Yang, L.; Rogan, E.G.; Cavalieri, E.L. Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic. Biol. Med., 2008, 45(2), 136-145.
218. Lu, F.; Zahid, M.; Wang, C.; Saeed, M.; Cavalieri, E.L.; Rogan, E.G. Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev. Res., 2008, 1(2), 135-145.
219. Guengerich, F.P.; Chun, Y.J.; Kim, D.; Gillam, E.M.J.; Shimada, T. Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat. Res., 2003, 523-524, 173-182. (Pubitemid 36293244)
220. Zahid, M.; Gaikwad, N.W.; Rogan, E.G.; Cavalieri, E.L. Inhibition of depurinating estrogen-DNA adduct formation by natural compounds. Chem. Res. Toxicol., 2007, 20(12), 1947-1953.
221. Csaki, C.; Keshishzadeh, N.; Fischer, K.; Shakibaei, M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem. Pharmacol., 2008, 75(3), 677-687.
222. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest., 2001, 107(3), 241-246.
223. Tak, P.P.; Firestein, G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest., 2001, 107(1), 7-11.
224. Handel, M.L.; McMorrow, L.B.; Gravallese E.M. Nuclear factorkappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum., 1995, 38(12), 1762-1770.
225. Ding, G.J.; Fischer, P.A.; Boltz, R.C.; Schmidt, J.A.; Colaianne, J.J.; Gough, A., Rubin, R.A.and Miller, D.K. Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin- 1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J. Biol. Chem., 1998, 273(44), 28897-28905. (Pubitemid 28507582)
226. Shakibaei, M.; John, T.; Schulze-Tanzil, G.; Lehmann, I.; Mobasheri, A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase- 9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem. Pharmacol., 2007, 73(9), 1434-1445. (Pubitemid 46452591)
227. Shakibaei, M.; Csaki, C.; Nebrich, S.; Mobasheri, A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem. Pharmacol., 2008, 76(11), 1426-1439.
228. Dirks Naylor, A.J. Cellular effects of resveratrol in skeletal muscle. Life Sci., 2009, 84(19-20), 637-640.
229. Mann, J.R.; Backlund, M.G.; DuBois, R.N. Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol., 2005, 2(4), 202-210.
230. Surh, Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer,0 2003, 3(10), 768-780. (Pubitemid 37328815)
231. Pezzuto, J.M. Resveratrol: a whiff that induces a biologically specific tsunami. Cancer Biol. Ther., 2004, 3(9), 889-890.
232. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomark. Prev., 2007, 16(6), 1246-1252.
233. Mishra, R.; Sellin, D.; Radovan, D.; Gohlke, A.; Winter, R. Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol. Chembiochem, 2009, 10(3), 445-449.